$3.77
00.00%
Last update: 4:00 PM
15 minutes delayed
Prelude Therapeutics
PRLDNASDAQ
Prelude Therapeutics (NASDAQ:PRLD) Stock, Analyst Ratings, Price Targets, Predictions
Prelude Therapeutics Inc has a consensus price target of $10.14, established from looking at the 22 latest analyst ratings. The last 3 analyst ratings were released from JMP Securities, HC Wainwright & Co., and Morgan Stanley on March 13, 2024, February 20, 2024, and December 19, 2023. With an average price target of $5.33 between JMP Securities, HC Wainwright & Co., and Morgan Stanley, there's an implied 41.09% upside for Prelude Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
JMP Securities
HC Wainwright & Co.
Morgan Stanley
Barclays
B of A Securities
1calculated from analyst ratings
Analyst Ratings for Prelude Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/13/2024 | Buy Now | 85.19% | JMP Securities | Reni Benjamin | → $7 | Initiates | → Market Outperform | Get Alert |
| 02/20/2024 | Buy Now | 32.28% | HC Wainwright & Co. | Robert Burns | → $5 | Downgrade | Buy → Neutral | Get Alert |
| 12/19/2023 | Buy Now | 5.82% | Morgan Stanley | Jeffrey Hung | $10 → $4 | Downgrade | Equal-Weight → Underweight | Get Alert |
| 11/07/2023 | Buy Now | 32.28% | HC Wainwright & Co. | Robert Burns | $6 → $5 | Maintains | Buy | Get Alert |
| 10/19/2023 | Buy Now | 58.73% | HC Wainwright & Co. | Robert Burns | $17 → $6 | Maintains | Buy | Get Alert |
| 08/17/2023 | Buy Now | 349.74% | HC Wainwright & Co. | Robert Burns | → $17 | Reiterates | Buy → Buy | Get Alert |
| 08/04/2023 | Buy Now | 164.55% | Morgan Stanley | Jeffrey Hung | $10 → $10 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 08/04/2023 | Buy Now | 32.28% | Barclays | Peter Lawson | $7 → $5 | Maintains | Equal-Weight | Get Alert |
| 03/17/2023 | Buy Now | 349.74% | HC Wainwright & Co. | Robert Burns | $15 → $17 | Maintains | Buy | Get Alert |
| 11/21/2022 | Buy Now | 58.73% | B of A Securities | Tazeen Ahmad | → $6 | Downgrade | Neutral → Underperform | Get Alert |
| 11/17/2022 | Buy Now | 296.83% | HC Wainwright & Co. | Robert Burns | $16 → $15 | Maintains | Buy | Get Alert |
| 11/15/2022 | Buy Now | 164.55% | Morgan Stanley | Jeffrey Hung | $11 → $10 | Maintains | Equal-Weight | Get Alert |
| 09/09/2022 | Buy Now | 191.01% | Morgan Stanley | Jeffrey Hung | $19 → $11 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 07/29/2022 | Buy Now | 138.1% | Jefferies | Roger Song | → $9 | Initiates | → Buy | Get Alert |
| 05/12/2022 | Buy Now | 323.28% | HC Wainwright & Co. | Robert Burns | $62 → $16 | Maintains | Buy | Get Alert |
| 03/17/2022 | Buy Now | 402.65% | Morgan Stanley | Jeffrey Hung | $20 → $19 | Maintains | Overweight | Get Alert |
| 03/15/2022 | Buy Now | 164.55% | B of A Securities | Tazeen Ahmad | $50 → $10 | Downgrade | Buy → Neutral | Get Alert |
| 02/28/2022 | Buy Now | 217.46% | Barclays | Peter Lawson | $20 → $12 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 11/17/2021 | Buy Now | 429.1% | Barclays | Peter Lawson | — | Maintains | Overweight | Get Alert |
| 10/11/2021 | Buy Now | 825.93% | Morgan Stanley | — | — | Upgrade | Equal-Weight → Overweight | Get Alert |
| 10/08/2021 | Buy Now | 773.02% | Barclays | Peter Lawson | — | Maintains | Overweight | Get Alert |
| 07/27/2021 | Buy Now | 1487.3% | B of A Securities | Tazeen Ahmad | — | Upgrade | Neutral → Buy | Get Alert |
FAQ
What is the target price for Prelude Therapeutics (PRLD) stock?
The latest price target for Prelude Therapeutics (NASDAQ:PRLD) was reported by JMP Securities on March 13, 2024. The analyst firm set a price target for $7.00 expecting PRLD to rise to within 12 months (a possible 85.68% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Prelude Therapeutics (PRLD)?
The latest analyst rating for Prelude Therapeutics (NASDAQ:PRLD) was provided by JMP Securities, and Prelude Therapeutics initiated their market outperform rating.
When was the last upgrade for Prelude Therapeutics (PRLD)?
The last upgrade for Prelude Therapeutics Inc happened on October 11, 2021 when Morgan Stanley raised their price target to $35. Morgan Stanley previously had an equal-weight for Prelude Therapeutics Inc.
When was the last downgrade for Prelude Therapeutics (PRLD)?
The last downgrade for Prelude Therapeutics Inc happened on February 20, 2024 when HC Wainwright & Co. changed their price target from N/A to $5 for Prelude Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Prelude Therapeutics (PRLD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Prelude Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Prelude Therapeutics was filed on March 13, 2024 so you should expect the next rating to be made available sometime around March 13, 2025.
Is the Analyst Rating Prelude Therapeutics (PRLD) correct?
While ratings are subjective and will change, the latest Prelude Therapeutics (PRLD) rating was a initiated with a price target of $0.00 to $7.00. The current price Prelude Therapeutics (PRLD) is trading at is $3.77, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.